Morgan Stanley
BBLG

Morgan Stanley’s Bone Biologics BBLG Stock Holding History

Morgan Stanley’s Portfolio BBLG Stock Details BBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4,755
Closed -$60.8K – 7975
2024
Q3 		$60.8K Buy
+4,755
New +$45.1K ﹤0.01% 6158
2023
Q1 		– Hold
0
– -$2 – 7712
2022
Q4 		– Hold
0
– – – 7852

Other funds holding BBLG

UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

Morgan Stanley's BBLG Position: Q4 2024 in Review

Morgan Stanley sold out of Bone Biologics (BBLG) in Q4 2024, closing a stake of 4,755 shares — an estimated $60.8K sold.

Morgan Stanley first reported a position in BBLG in Q3 2024 and held it in 1 quarter. The position peaked at $60.8K in Q3 2024. 6 funds tracked by Wall St. Rank hold BBLG as of Q4 2024.

  • Morgan Stanley reported no remaining Bone Biologics position as of Q4 2024 after selling out during the quarter.
  • Morgan Stanley sold 4,755 Bone Biologics shares in Q4 2024, an estimated $60.8K.
  • Morgan Stanley first reported a position in Bone Biologics in Q3 2024 and held it in 1 quarter.
  • Morgan Stanley's Bone Biologics position peaked at $60.8K in Q3 2024.
  • 6 funds tracked by Wall St. Rank held Bone Biologics as of Q4 2024.

Based on Morgan Stanley's 13F filing for Q4 2024, filed 14 Feb 2025.